Oncosec Medical Inc (ONCS) 10-Q Quarterly Report March 2019

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jan. 31, 2019	Mar. 08, 2019
Document And Entity Information
Entity Registrant Name	ONCOSEC MEDICAL Inc
Entity Central Index Key	0001444307
Document Type	10-Q
Document Period End Date	Jan. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		64,793,769
Trading Symbol	ONCS
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1444307/000149315219003049/form10-q.htm

View differences made from one quarter to another to evaluate Oncosec Medical Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Oncosec Medical Inc.

Continue

Assess how Oncosec Medical Inc's management team is paid from their Annual Proxy

Oncosec Medical Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

Legal

Other

Filter Subcategory:

All

Debt

Product

Expense

Income

Earnings

Other

Inside Oncosec Medical Inc's 10-Q Quarterly Report:

Financial - Debt Highlight
If we incur debt, our fixed payment obligations, liabilities and leverage relative to our equity capitalization would increase, which could increase the cost of future capital.

Financial - Debt Highlight
Further, the terms of any debt securities we issue or borrowings we incur, if available, could impose significant restrictions on our operations, such as limitations on our ability to incur additional debt or issue additional equity or other operating restrictions that could adversely affect our ability to conduct our business, and any such debt could be secured by any or all of our assets pledged as collateral.
Revenue - Product Highlight
The increase in cash provided by investing activities was related to maturities and sales of certain investment securities.
Financial - Shares Highlight
Changes in assumptions used under the Black-Scholes option valuation model could materially affect the Companys net loss and net loss per share.
Other - Other Highlight
This increase was primarily due to an increase in cash, cash equivalents and short-term investment securities from $27.0 million as of July 31, 2018 to $28.7 million as of January 31, 2019, which is attributable to the net proceeds received from our Alpha Holdings, Inc. stock purchase agreement and certain stock option exercises (see "Sources of Capital" below).
Financial - Expense
This decrease was primarily due...Read more
Other - Other
Weak economic and capital market...Read more
Other - Other
In light of these risks,...Read more
Other - Other
This increase was primarily due...Read more
Other - Other
This increase was primarily due...Read more
Other - Other
Employee Stock Purchase Plan Employees...Read more
Other - Other
If we cannot raise the...Read more
Other - Other
The $2.0 million increase in...Read more
Financial - Expense
Our general and administrative expenses...Read more
Financial - Expense
Our general and administrative expenses...Read more
Financial - Expense
This decrease was primarily due...Read more
Other - Other
If a change were to...Read more
Other - Other
Forward-looking statements are only predictions...Read more
Financial - Expense
Assets to be disposed of...Read more
Financial - Shares
The warrants issued during the...Read more
Financial - Shares
Controlled Equity Offering Sales Agreement...Read more
Financial - Income
Examples of such circumstances may...Read more
Other - Other
Accounting for Long-Lived Assets We...Read more
Financial - Expense
Our research and development expenses...Read more
Financial - Expense
Our research and development expenses...Read more
Financial - Shares
Alpha Holdings On August 31,...Read more
Legal - Other
We have also used our...Read more
Financial - Income
Other income, net, increased by...Read more
Financial - Income
Other income, net, increased by...Read more
Financial - Shares
The stock purchase plan allows...Read more
Other - Other
We expect to use our...Read more
Financial - Earnings
If management determines that a...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Oncosec Medical Inc provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: ONCS
CIK: 1444307
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-19-003049
Submitted to the SEC: Fri Mar 08 2019 5:11:37 PM EST
Accepted by the SEC: Fri Mar 08 2019
Period: Thursday, January 31, 2019
Industry: Pharmaceutical Preparations